We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
AVDL

Price
7.68
Stock movement up
+0.55 (7.71%)
Company name
Avadel Pharmaceuticals PLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
739.36M
Ent value
794.37M
Price/Sales
5.35
Price/Book
9.90
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
11.29
PEG
-
EPS growth
-4.78%
1 year return
-52.45%
3 year return
4.66%
5 year return
-1.52%
10 year return
-8.60%
Last updated: 2025-04-11

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

AVDL does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales5.35
Price to Book9.90
EV to Sales5.75

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count96.27M
EPS (TTM)-0.75
FCF per share (TTM)-0.86

Income statement

Loading...
Income statement data
Revenue (TTM)138.16M
Gross profit (TTM)127.00M
Operating income (TTM)-64.00M
Net income (TTM)-72.58M
EPS (TTM)-0.75
EPS (1y forward)0.68

Margins

Loading...
Margins data
Gross margin (TTM)91.92%
Operating margin (TTM)-46.33%
Profit margin (TTM)-52.53%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash28.58M
Net receivables37.10M
Total current assets127.26M
Goodwill16.84M
Intangible assets0.00
Property, plant and equipment13.76M
Total assets158.25M
Accounts payable7.92M
Short/Current long term debt1.94M
Total current liabilities42.78M
Total liabilities83.59M
Shareholder's equity74.66M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-82.81M
Capital expenditures (TTM)6.00
Free cash flow (TTM)-82.81M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-97.20%
Return on Assets-45.86%
Return on Invested Capital-96.27%
Cash Return on Invested Capital-109.84%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open7.11
Daily high7.70
Daily low7.00
Daily Volume1.17M
All-time high42.85
1y analyst estimate24.70
Beta1.63
EPS (TTM)-0.75
Dividend per share-
Ex-div date-
Next earnings date6 May 2025

Downside potential

Loading...
Downside potential data
AVDLS&P500
Current price drop from All-time high-82.08%-12.89%
Highest price drop-97.50%-56.47%
Date of highest drop26 May 20229 Mar 2009
Avg drop from high-71.18%-11.07%
Avg time to new high210 days12 days
Max time to new high5426 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AVDL (Avadel Pharmaceuticals PLC) company logo
Marketcap
739.36M
Marketcap category
Small-cap
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Employees
154
Investor relations
-
SEC filings
CEO
Gregory J. Divis
Country
USA
City
Dublin
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...